The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS).
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial
Bisogno, Gianni;
2021
Abstract
The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
defachelles-et-al-2021-randomized-phase-ii-trial-of-vincristine-irinotecan-with-or-without-temozolomide-in-children-and.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Accesso gratuito
Dimensione
364.37 kB
Formato
Adobe PDF
|
364.37 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
